Patents by Inventor Keith R. Yamamoto

Keith R. Yamamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for modulating nuclear receptor coactivator binding
    Patent number: 6965850
    Abstract: The present invention relates to methods and agonist/antagonist compounds for modulating nuclear receptor coactivator binding. The invention includes a method for identifying residues comprising a coactivator binding site for a nuclear receptor of interest. Also included is a method of identifying agonists and/or antagonists that bind to a coactivator binding site of a nuclear receptor of interest. Agonists and antagonists of coactivator binding to nuclear receptors also are provided. The invention is exemplified by identification and manipulation of the coactivator binding site of the thyroid receptor (TR), and compounds that bind to this sites. The methods can be applied to other nuclear receptors including RAR, RXR, PPAR, VDR, ER, GR, PR, MR, and AR.
    Type: Grant
    Filed: March 30, 1999
    Date of Patent: November 15, 2005
    Assignee: The Regents of the University of California
    Inventors: John D. Baxter, Beatrice Darimont, Weijun Feng, Robert J. Fletterick, Peter J. Kushner, Richard L. Wagner, Brian L. West, Keith R. Yamamoto
  • METHODS AND COMPOUNDS FOR MODULATING NUCLEAR RECEPTOR COACTIVATOR BINDING
    Publication number: 20020061539
    Abstract: The present invention relates to methods and agonist/antagonist compounds for modulating nuclear receptor coactivator binding. The invention includes a method for identifying residues comprising a coactivator binding site for a nuclear receptor of interest. Also included is a method of identifying agonists and/or antagonists that bind to a coactivator binding site of a nuclear receptor of interest. Agonists and antagonists of coactivator binding to nuclear receptors also are provided. The invention is exemplified by identification and manipulation of the coactivator binding site of the thyroid receptor (TR), and compounds that bind to this sites. The methods can be applied to other nuclear receptors including RAR, RXR, PPAR, VDR, ER, GR, PR, MR, and AR.
    Type: Application
    Filed: March 30, 1999
    Publication date: May 23, 2002
    Inventors: JOHN D. BAXTER, BEATRICE DARIMONT, WEIJUN FENG, ROBERT J. FLETTERICK, PETER J. KUSHNER, RICHARD L. WAGNER, BRIAN L. WEST, KEITH R. YAMAMOTO
  • Transition in transcriptional activation by intracellular hormone receptors at the tumor stage of dermal fibrosarcoma development
    Patent number: 5631133
    Abstract: Intracellular hormone receptors are discovered to undergo posttranslational regulation. Assays to assess cancer progression and to permit discovery of a new class of biologically active compounds are provided. Related kits are also provided.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: May 20, 1997
    Assignee: The Regents of the University of California
    Inventors: Douglas Hanahan, Keith R. Yamamoto, Maria d. M. Vivanco
  • Super glucocorticoid receptors: receptors with increased affinity and specificity for glucocorticoid steriods
    Patent number: 5215916
    Abstract: The present invention relates to novel glucocorticoid receptors that have greater affinity and specifity for glucocorticoid steroids than the naturally occurring receptors. More particularly, the invention relates to the altering of the equivalent of cysteine-656 of the rat glucocorticoid receptor to either serine or glycine for the production of super glucocorticoid receptors which retain full biological activity in intact cells and have higher affinity and specificity for glucocorticoid steroid binding than the original receptor. The invention further relates to the recombinant expression of such altered receptors in host cells.
    Type: Grant
    Filed: June 19, 1991
    Date of Patent: June 1, 1993
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Samuel S. Simons, Jr., Pradip K. Chakraborti, Keith R. Yamamoto, Michael J. Garabedian
  • Enhanced production of recombinant proteins in myeloma cells
    Patent number: 4889802
    Abstract: A mammalian myeloma cell comprising a double-stranded DNA molecule in its genome containing a coding sequence encoding a non-immunoglobulin protein, a non-immunoglobulin promoter sequence adjacent to the 5' terminus of said coding sequence, and the 8-base pair nucleotide sequence 5'-ATTTGCAT-3' located 5' to the transcription initiation site of said promoter sequence. The DNA molecule may optionally contain an enhancer element. Methods of producing non-immunoglobulin protein and DNA molecules are also provided.
    Type: Grant
    Filed: September 24, 1986
    Date of Patent: December 26, 1989
    Assignee: The Regents of the University of California
    Inventors: Tristram G. Parslow, Keith R. Yamamoto